BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 19, 2026
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

July 19, 2010

View Archived Issues

Researchers cite ways to regulate conflicts of interest

Academic scientists seeking financial support of their work tend to find themselves in a bit of a pickle. They need funding, often provided by industry, to help spur innovation through their research, but that support tends to result in – either real or perceived – bias in favor of their industry partner. (Medical Device Daily) Read More

Stentys enrolls final patient in its APPOSITION II study

Read More

Report from Europe: ClariVein vein ablation system introduced in Europe

Read More

Washington roundup: FDA eyes public information campaigns for med-tech items

Read More

Deals roundup: ON Semiconductor to purchase Sanyo subsidiary for $366M

Read More

MDD's food for med-tech thought

Read More

Financings roundup: BioMimetic prices offering, seeks to raise $40 million

Read More

Court report: Zoll in suit against Philips over several patents

Read More

People in the News

Read More

People in the News

Read More

Agreements/contracts: Eurotech to supply computers to blood management OEM

Read More

Grants roundup: Johns Hopkins receives $34.5 million to develop MPL

Read More

Product Briefs

Read More

MDD's Diagnostic Extra

Read More

Challenges linger, but VCs see promise in device side

Venture capitalists in this industry have a lot weighing on their mind these days: an increasingly erratic regulatory process, new FDA leadership, healthcare reform, growing economic uncertainty in Europe, and the U.S. economy is just now beginning to rebound after a difficult 2008 and 2009. (Medical Device Daily) Read More

Financings roundup: RoundTable reports closing on $800M in equity funds

Read More

International report: Lantheus launches Definity imaging agent in India

Read More

Washington roundup: Senate mirrors administration on FDA budget for fiscal 2011

Read More

MDD's food for med-tech thought

Read More

Grants roundup: MJFF committed to spend $12M or Parkinson's research

Read More

Patent watch: Ingen enter diabetes drug market with new product

Read More

Agreements/contracts: Purdue, Techshot partner to access new technology

Read More

People in the News

Read More

Med-Tech Notes

Read More

Deals roundup: GHP, PCF purchase Sterimed for undisclosed amount

Read More

Product Briefs

Read More

MDD's Neurology Extra

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing